Clinical Trials Results
|
Results for the search you initiated will be displayed below.
-
Click here for details...
This phase III trial studies how well lenalidomide in combination with ixazomib works
compared to lenalidomide alone in treating patients with evidence of residual multiple
myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of
multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better
than giving lenalidomide alone in treating patients with evidence of residual multiple
myeloma after a stem cell transplantation.
-
Click here for details...
This phase III trial studies how well lenalidomide and dexamethasone works with or without
daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in
chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab,
may induce changes in the body's immune system and may interfere with the ability of tumor
cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work
better in treating patients with smoldering myeloma.
-
Click here for details...
This phase III trial compares the combination of four drugs (daratumumab, bortezomib,
lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab,
lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody
that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory
drugs, such as dexamethasone lower the body's immune response and are used with other drugs
in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and
dexamethasone may be more effective in shrinking the cancer or preventing it from returning,
compared to continuing on daratumumab, lenalidomide, and dexamethasone.
-
Click here for details...
This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Genetic
tests look at the unique genetic material (genes) of patients' tumor cells. Patients with
genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more
from treatment which targets their tumor's particular genetic abnormality. Identifying these
genetic abnormalities first may help doctors plan better treatment for patients with solid
tumors, lymphomas, or multiple myeloma.
-
Click here for details...
This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Genetic
tests look at the unique genetic material (genes) of patients' tumor cells. Patients with
genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more
from treatment which targets their tumor's particular genetic abnormality. Identifying these
genetic abnormalities first may help doctors plan better treatment for patients with solid
tumors, lymphomas, or multiple myeloma.
|
